INTRODUCTION
Lung cancers are the leading cause of brain metastases, and these brain metastases are a common cause of cancer-related morbidity and mortality. Among patients with epidermal growth factor receptor (EGFR)-mutant lung cancers, nearly 25% have brain metastases at the time of the diagnosis of metastatic disease. 1 The majority of patients with EGFR-mutant lung cancers will respond initially to EGFR tyrosine kinase inhibitors (TKIs), but resistance to these agents typically develops. 2, 3 Because the central nervous system (CNS) is also a frequent site of disease progression, the cumulative incidence of CNS metastases approaches 60% in patients with EGFR-mutant lung cancers. Up to 33% of patients with EGFR-mutant lung cancers have CNS progression while they are on initial EGFR TKI therapy. Isolated CNS progression often occurs in the setting of continued systemic control. 4, 5 Cerebrospinal fluid (CSF) concentrations of erlotinib are 3% to 5% of the concentrations in concurrent plasma samples, 6 and this suggests that CNS-only progression may be due to inadequate drug delivery as well as tumoral drug resistance. Pulse-dose erlotinib results in higher CSF concentrations and may be more effective in the treatment of CNS metastases. 7, 8 In addition, when resistance mechanisms are assessed by the molecular testing of tumor samples from both the CNS and systemic disease sites, the CNS metastases often do not harbor resistance mutations such as EGFR T790M. 9 Preclinical work incorporating evolutionary mathematical modeling suggested that intermittent pulse doses of erlotinib in conjunction with continuous low-dose administration would delay the establishment of resistant cell populations. 10 On the basis of these concepts and preclinical data, 10 we previously tested the schedule of twice weekly pulse (high-dose) erlotinib and continuous daily (low-dose) erlotinib as an initial treatment for patients with EGFR-mutant lung cancers.
We defined the maximum tolerated dose of erlotinib as 1200 mg on days 1 and 2 and as 50 mg on days 3 to 7.
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Although this regimen did not delay the time to acquired resistance or prevent the emergence of T790M, no patient developed progression in the CNS. To follow up on this unexpected observation, we treated an additional cohort of patients with untreated brain metastases or leptomeningeal disease with this regimen.
MATERIALS AND METHODS
This trial was an expansion cohort of a prospective, openlabel, single-center, phase 1 dose-escalation study in patients with EGFR-mutant lung cancers. 11 The trial was conducted after approval of the institutional review board at Memorial Sloan Kettering. The primary endpoints of the study were the overall and CNS responses according to version 1.1 of the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Secondary endpoints included progression-free survival and overall survival.
Patients had stage IV or recurrent EGFR-mutant lung adenocarcinomas with brain metastases or leptomeningeal disease. Patients were eligible if they had received no prior treatment with an EGFR TKI and no prior radiation to the CNS. Prior cytotoxic chemotherapy was allowed. Patients were required to have measurable disease per RECIST 1.1. Patients must have had adequate organ function and a Karnofsky performance status 70%.
Study Design
All patients received initial daily doses of erlotinib of 1200 mg on days 1 and 2 and 50 mg on days 3 to 7 weekly with no planned treatment breaks; the same dose, schedule, and dose reduction scheme had been established in the earlier phase 1 study. 11 Erlotinib was continued until disease progression or intolerable toxicity.
Study Assessments
Patients were assessed weekly during the initial 28 days and then every 21 days. At each visit, the patient history was taken, and a physical examination, a complete blood count, and serum chemistries were performed. Toxicity was graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4). The response to therapy was assessed every 6 weeks with a contrast computed tomography scan and a head magnetic resonance imaging scan, with the response evaluated according to RECIST 1.1. After 18 weeks of treatment, we performed radiographic assessments every 12 weeks.
Statistical Analysis
Progression-free survival was estimated with the KaplanMeier method and was defined as the time from the start of erlotinib until progression or death. Patients were censored on the date they came off the study or on the date of their last assessment if they were still receiving the study therapy. Response rates were calculated with binomial proportions and exact 95% confidence intervals (CIs). All statistical analyses were performed with R 3.2.2 (R Development Core Team).
RESULTS

Patients
We enrolled 19 patients with EGFR-mutant lung cancers and untreated CNS metastases from May 2015 to August 2016. The median age was 61 years (range, 45-80 years). Seventy-four percent of the patients were women; 32% of the patients had received platinum doublet chemotherapy. Forty-two percent of the patients had target brain lesions (according to RECIST 1.1), with the remainder having nontarget lesions. The median size of the target brain lesions was 13 mm (range, 10-19 mm), and the median number of brain metastases per patient was 4 (range, 1-78). One patient had leptomeningeal disease with positive CSF cytology at enrollment. Thirty-two percent of the patients were on dexamethasone for cerebral edema at study entry. The clinical characteristics of all patients are listed in Table 1 . Fourteen patients had partial responses (overall response rate, 74%; 95% CI, 51%-89%; Fig. 1 ). One patient came off the study because of toxicity before the first follow-up radiographic assessment and was counted as a nonresponder. The median progression-free survival was 9.7 months (95% CI, 7.0 months to not reached). Seventeen of the 19 patients were still alive with a median follow-up of 15 months. Thirteen discontinued pulse erlotinib because of the progression of their disease. All 13 patients had EGFR T790M testing performed at progression, and 5 (38%; 95% CI, 18%-65%) were found to have acquired EGFR T790M. All biopsies were of systemic sites of disease.
CNS Activity
The objective response rate for the 8 patients with measurable brain metastases was 75% (95% CI, 40%-94%; Fig.  2 ). In addition, among the 11 patients with nontarget brain lesions, we observed 6 patients with lesions initially present that were then noted to be absent during study treatment. The patient with leptomeningeal disease showed clinical improvement with decreased facial pain and numbness as well as radiologic improvement with decreased enhancement of the meninges. Four of the 6 patients on dexamethasone at study entry were able to discontinue it. Only 3 of the 19 patients, all with brain metastases at presentation, developed disease progression in the CNS. One had progression only in existing brain metastases, 1 developed a new brain metastasis, and 1 patient had both CNS and systemic progression.
Toxicity
All 19 patients were evaluable for toxicity (Table 2 ). There were no grade 4 toxicities or deaths from any cause during the study. Three patients were removed from the study for toxicity (1 for dizziness, 1 for nausea and vomiting, and 1 for transaminitis). All 3 then continued on daily erlotinib. Fourteen of the 19 patients required a reduction of the pulse dose. The median pulse dose delivered after 3 months on the study was 1050 mg on days 1 and 2 of each week.
Patient Disposition
As of April 2017, 3 patients remained in the study. Thirteen patients had discontinued the study therapy because of progressive disease, and 3 others had discontinued it because of adverse events. Four individuals required radiation to brain metastases at some time during their illness. No patient died during the study.
DISCUSSION
This is the first prospective trial to evaluate the use of pulse/continuous-dose erlotinib in patients with untreated brain metastases. The 74% overall objective response rate and the 10-month median progression-free survival were similar to the findings of reports with standard doses of erlotinib. 3 Although this dose and schedule of erlotinib did not improve overall outcomes, CNS control was impressive, with only 3 patients experiencing progression in the CNS. This low rate of progression is especially notable for this population of patients, all of whom had CNS metastases untreated with radiation or surgery at the start of the study. Furthermore, in this population, everyone could have received CNS radiation at diagnosis, but only 4 of the 19 patients received it subsequently; this potentially spared them from the potential adverse effects of CNS radiation. Pulse/continuous-dose erlotinib may prevent pharmacologic erlotinib resistance in the CNS, but it did not delay the emergence of T790M.
It is challenging to compare the duration of CNS disease control with standard dosing schedules of erlotinib because none of the reports of large studies of EGFR TKIs include this information. 12 Prospective trials in patients with brain metastases have either included a substantial portion of patients previously receiving wholebrain or stereotactic radiation 13 or evaluated the combination of an EGFR TKI with radiation. 14 Although there have been reports of the use of high pulse doses of EGFR TKIs to treat CNS metastases, these are all retrospective, with partial responses uncommon and rarely durable. 7 These previous reports used pulse-dose EGFR TKIs in the setting of progressive disease during EGFR TKI therapy and not as first-line EGFR TKI treatments. The efficacy of pulse-dose EGFR TKIs would presumably be markedly different in the salvage setting versus first-line treatment. There is emerging evidence that newer EGFR TKIs such as osimertinib and AZD3759 have superior CNS penetration, 15, 16 and prospective clinical trials testing these agents as first-line treatments in patients with EGFR-mutant lung cancers are currently ongoing (NCT02228369).
In our earlier phase 1 trial, pulse/continuous-dose erlotinib demonstrated side effects comparable to those seen in studies of erlotinib at 150 mg daily. 17 This report again demonstrates that pulse/continuous-dose erlotinib is tolerated by most people with CNS metastases. The regimen was discontinued for toxicity in 3 patients, all of whom remained on erlotinib.
This study of pulse/continuous-dose erlotinib has demonstrated that systemic therapies for persons with lung cancers work equally well in extracranial sites and the CNS for patients with untreated CNS metastases. This regimen controls CNS disease and could be useful in situations in which CNS control is critical. Pulse/continuous-dose erlotinib is an effective regimen for patients with EGFR-mutant lung cancers and brain metastases, even when they have symptomatic CNS disease. With CNS metastases affecting a large proportion of patients with EGFR-mutant lung cancers, a treatment regimen that effectively treats and prevents CNS metastases and may postpone or obviate the need for CNS radiotherapy is a valuable option for select patients.
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